Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
…, SI Sherman, J Krajewska, CC Lin, F Vaisman… - The Lancet …, 2021 - thelancet.com
Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC) previously
treated with vascular endothelial growth factor receptor (VEGFR)-targeted therapy have …
treated with vascular endothelial growth factor receptor (VEGFR)-targeted therapy have …
Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy
F Vaisman, D Momesso, DA Bulzico… - Clinical …, 2012 - Wiley Online Library
Objective To validate the A merican T hyroid A ssociation ( ATA ) initial risk of recurrence
scheme and the M emorial S loan K ettering C ancer C enter ( MSKCC ) response to therapy re‐…
scheme and the M emorial S loan K ettering C ancer C enter ( MSKCC ) response to therapy re‐…
Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease …
F Vaisman, A Shaha, S Fish… - Clinical …, 2011 - Wiley Online Library
Objective To describe the risk of structural disease recurrence in a cohort of patients with
differentiated thyroid cancer selected for treatment with either thyroid lobectomy or total …
differentiated thyroid cancer selected for treatment with either thyroid lobectomy or total …
Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine
DP Momesso, F Vaisman, SP Yang… - The Journal of …, 2016 - academic.oup.com
Context: Although response to therapy assessment is a validated tool for dynamic risk
stratification in patients with differentiated thyroid cancer (DTC) treated with total thyroidectomy (TT…
stratification in patients with differentiated thyroid cancer (DTC) treated with total thyroidectomy (TT…
An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer
…, F Vaisman, R Corbo, D Momesso, M Vaisman… - Thyroid, 2016 - liebertpub.com
Background: Age is a critical factor in outcome for patients with well-differentiated thyroid
cancer. Currently, age 45 years is used as a cutoff in staging, although there is increasing …
cancer. Currently, age 45 years is used as a cutoff in staging, although there is increasing …
Survival from differentiated thyroid cancer: what has age got to do with it?
…, F Vaisman, D Momesso, R Corbo, M Vaisman… - Thyroid, 2015 - liebertpub.com
Background: In most staging systems, 45 years of age is used to differentiate low risk thyroid
cancer from high risk thyroid cancer. However, recent studies have questioned both the …
cancer from high risk thyroid cancer. However, recent studies have questioned both the …
In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete …
F Vaisman, H Tala, R Grewal, RM Tuttle - Thyroid, 2011 - liebertpub.com
Background: We previously demonstrated the clinical utility of using response to therapy
variables obtained during the first 2 years of follow-up to actively modify initial risk estimates …
variables obtained during the first 2 years of follow-up to actively modify initial risk estimates …
[HTML][HTML] Thyroid carcinoma in children and adolescents—systematic review of the literature
F Vaisman, R Corbo, M Vaisman - Journal of Thyroid Research, 2011 - hindawi.com
Thyroid cancer in children and adolescents is usually a major concern for physicians, patients,
and parents. Controversies regarding the aggressiveness of the clinical presentation and …
and parents. Controversies regarding the aggressiveness of the clinical presentation and …
[HTML][HTML] Genetic landscape of papillary thyroid carcinoma and nuclear architecture: an overview comparing pediatric and adult populations
A Rangel-Pozzo, L Sisdelli, MIV Cordioli, F Vaisman… - Cancers, 2020 - mdpi.com
Simple Summary Papillary thyroid carcinoma (PTC) represents 80–90% of all differentiated
thyroid carcinomas. PTC has a high rate of gene fusions and mutations, which can influence …
thyroid carcinomas. PTC has a high rate of gene fusions and mutations, which can influence …
Molecular markers involved in tumorigenesis of thyroid carcinoma: focus on aggressive histotypes
GC Penna, F Vaisman, M Vaisman… - … and genome research, 2017 - karger.com
Thyroid cancer derived from follicular cells (TCDFC) comprises well-differentiated (papillary
and follicular) carcinoma, poorly differentiated carcinoma, and anaplastic carcinoma. …
and follicular) carcinoma, poorly differentiated carcinoma, and anaplastic carcinoma. …